Mabpharm Limited (2181) AI Stock Analysis

• Market Cap: HK$1.67B
• Dividend Yield: N/A
• Average Volume (3M): 354.33K
• Price to Earnings (P/E): 157.6
• Beta (1Y): 0.98
• Revenue Growth: 178.36%
• EPS Growth: 86.74%
• Country: HK
• Employees: 315
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): <0.01
• Shares Outstanding: 4,124,080,000
• 10 Day Avg. Volume: 54,400
• 30 Day Avg. Volume: 354,333
• PEG Ratio: 0.22
• Price to Book (P/B): 12.19
• Price to Sales (P/S): 4.20
• P/FCF Ratio: -17.06
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: HK$0.51 ▲(1.40% Upside)
• Action: Upgraded Date: 12/03/25
• Date: Action: Upgraded 12/03/25

Mabpharm Limited faces significant financial challenges, with high leverage and negative cash flows being the most critical factors. Technical indicators suggest a bearish trend, and the valuation is unattractive due to ongoing losses. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

A nearly 200% year-over-year revenue increase indicates meaningful top-line traction and growing market acceptance. Sustained revenue expansion provides operating leverage potential, funding runway for R&D and commercialization efforts, and a stronger negotiating position with partners over the coming months.

Improving EPS Trend

An 86.7% improvement in EPS reflects progress toward narrowing per-share losses, suggesting operational improvements or scaling benefits. If maintained, this trend supports stability in earnings power, reduces dependency on external dilution, and signals a path toward profitability over a medium-term horizon.

Organizational Scale / Talent Base

A workforce of 315 suggests sufficient organizational scale to run R&D, clinical operations, and commercial activities. In biotech, a stable headcount signals capacity to advance trials and regulatory programs, preserve institutional knowledge, and execute multi-stage development plans over the next several months.

Negative Factors

High Leverage

Substantial leverage (debt/equity 3.50) and a low equity ratio constrain financial flexibility and increase refinancing and covenant risk. In a capital-intensive biotech model, high debt amplifies vulnerability to cash shortfalls and limits ability to fund trials or scale operations without costly external financing.

Negative Cash Generation

Persistent negative operating and free cash flows force reliance on external capital, likely leading to dilution or expensive debt. This undermines long-term sustainability, elevates execution risk for development programs, and constrains the company’s ability to invest countercyclically or pursue partnerships.

Large Operating Losses / Low Margins

Deep negative margins near -50% indicate structural unprofitability despite revenue growth. Such wide losses reflect a cost base or R&D intensity that may prevent breakeven absent sustained revenue gains or expense control, weakening resilience and making multi-quarter recovery challenging.

Mabpharm Limited Business Overview & Revenue Model

Company Description

Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for allergic diseases, cancers, and autoimmune diseases in China. Its products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-IgE monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for moderate to severe active rheumatoid arthritis; and CMAB807 for osteoporosis indications. The company is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X for the treatment of tumor bone metastasis; and CMAB809 that is in Phase I clinical trial for the treatment of HER2 overexpressing breast cancer and metastatic gastric cancer. In addition, its products under the pre-clinical stage include CMAB810 for the treatment of breast cancer; CMAB816 for the treatment of periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; CMAB017 for the treatment of KRAS wild-type colorectal cancer; CMAB015, a biosimilar candidate for secukinumab to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a biosimilar candidate for mepolizumab, for the treatment of asthma and eosinophilic granulomatous polyangiitis; and CMAB022 for the treatment of inflammatory diseases. The company also involved in research and development, technical consulting, technology transfer, and technical services of biological products, diagnostic reagents, chemical biological reagents, and drugs. The company was incorporated in 2018 and is headquartered in Taizhou, the People's Republic of China.

How the Company Makes Money

Mabpharm Limited generates revenue primarily through the development and commercialization of its proprietary biologic drugs. The company's revenue model includes income from product sales once therapies receive regulatory approval and are launched in the market. Additionally, Mabpharm may enter into strategic partnerships and collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on future sales. These partnerships often involve co-development agreements, where Mabpharm shares research costs and receives a share of the profits, thereby diversifying its revenue streams. The company may also engage in licensing agreements for its technology or products, further contributing to its earnings.

Mabpharm Limited Financial Statement Overview

Summary

Mabpharm Limited shows strong revenue growth but remains unprofitable with significant financial instability. High leverage and negative cash flows indicate reliance on external financing and potential financial risks.

Income Statement

Mabpharm Limited has shown significant revenue growth of 196.24% from the previous year, indicating strong top-line expansion. However, the company remains unprofitable with a negative net profit margin of -49.55% and a negative EBIT margin of -46.34%. Despite the improvement in revenue, consistent losses over the years indicate challenges in achieving profitability.

Balance Sheet

The company exhibits a high debt-to-equity ratio of 3.50, reflecting substantial leverage and potential financial risk. The return on equity is negative at -143.89%, aligning with ongoing net losses. The equity ratio of 8.75% suggests limited equity as a proportion of total assets, further emphasizing financial instability.

Cash Flow

Mabpharm Limited's cash flow statements reveal challenges with cash generation, as evidenced by the absence of free cash flow and operating cash flow for the current period. Historical free cash flow has been negative, indicating ongoing cash management issues. The inability to generate positive operating cash flow relative to net income further highlights the need for operational improvements.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	423.93M	258.23M	87.16M	55.92M	82.88M	0.00
Gross Profit	366.28M	219.39M	75.24M	40.54M	66.11M	0.00
EBITDA	28.72M	-67.81M	-139.08M	-152.08M	-245.46M	-169.93M
Net Income	-27.48M	-127.95M	-209.36M	-210.62M	-291.74M	-188.57M
Balance Sheet
Total Assets	1.07B	1.02B	1.03B	917.52M	899.90M	1.16B
Cash, Cash Equivalents and Short-Term Investments	94.16M	89.34M	173.34M	48.61M	81.56M	484.85M
Total Debt	305.01M	293.09M	260.07M	126.34M	46.43M	40.35M
Total Liabilities	968.98M	927.28M	829.92M	516.58M	297.92M	281.55M
Stockholders Equity	98.86M	88.93M	205.06M	400.94M	601.98M	881.49M
Cash Flow
Free Cash Flow	53.59M	-63.58M	38.35M	-182.01M	-348.14M	-344.47M
Operating Cash Flow	103.11M	-4.10M	57.39M	-56.88M	-199.47M	-147.23M
Investing Cash Flow	-110.67M	-98.20M	-3.50M	-104.95M	-179.42M	156.00M
Financing Cash Flow	27.63M	18.28M	85.60M	112.26M	-17.78M	-80.48M

Mabpharm Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2181, the sentiment is Negative. The current price of 0.5 is above the 20-day moving average (MA) of 0.48, below the 50-day MA of 0.50, and below the 200-day MA of 0.56, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 16.99 is Positive, neither overbought nor oversold. The STOCH value of 7.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2181.

Mabpharm Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	60 Neutral	HK$3.11B	79.80	0.99%	―	9.41%	-32.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2181	45 Neutral	HK$1.67B	157.56	-25.72%	―	178.36%	86.74%
3681	45 Neutral	HK$2.72B	-10.54	-55.33%	―	-100.00%	30.68%
2185	44 Neutral	HK$1.12B	-7.24	-14.87%	―	―	22.65%
6978	43 Neutral	HK$1.48B	-2.55	―	―	―	27.90%
6996	41 Neutral	HK$2.45B	-5.39	-26.73%	―	49.64%	59.58%